|
Immune response rate
- Current market: limited maximum 30% immune response rate due to narrow antigen targets
- CancerVaccine™: use the immune system to its full potential to reach 100% immune response rate
Antigens
- Current market: therapeutic use limited due to specificity of antigens
- CancerVaccine™: targets simultaneously multiple cancer-specific antigens
Life span
- Current market: life span extension of only a few months due to targeting one or only a few cancer antigens with resultant residual cancer cell population
CancerVaccine™: kills 100% of all mutated cells, including pre-cancer cells and mature cancer cells, metastasized cancer cells and cancer stem cells, and extends life span.
CancerVaccine™ represents a broad and diverse group of products that can be developed from almost any primary or cultured cancer cell line or
type of enriched cancer stem cells. Each CancerVaccine™ is unique based upon the built-in genetic mutations resulting from the progenitor cancer cells.
CancerVaccine™ liposomes are foreign to immune systems since they do not have self-recognition molecular patterns on their surface. More
importantly, CancerVaccine™ preserves most, if not all, intracellular antigens available for enhanced antigen presentation processes.
After engulfment by macrophages and dendritic cells, fragmented antigens are able to bind to self-recognition molecular patterns on the
surfaces of macrophages and dendritic cells. These professional antigen presenters then migrate to lymph nodes where T-helper cells identify
them as either self or foreign on a one-by-one basis. “Foreign” antigens are recorded and stored in B-cells by DNA recombination. B-cells
then produce antibody according to the DNA recombination sequences. It is believed that the capacity of B-cell memory is about 109.
BioMedicur's CancerVaccine™ products are developed according to its proprietary cancer prevention and immunotherapy platform.
This platform employs CancerVaccine™ vaccination procedures to induce acquired immune responses against genetic mutations or antigens
in cancer cells specifically. CancerVaccine™ are a series of cancer vaccine products. CancerVaccine™
are non-tumorigenic and non-mutating heterogeneous derivatives or variants of cancer cells that induce adaptive or acquired immune responses against cancer cells.
|